Cart
sales@molnova.com
Xanthine oxidase-IN-9
CAS No. 2571069-61-7
Xanthine oxidase-IN-9( ——— )
Catalog No. M39675 CAS No. 2571069-61-7
Xanthine oxidase-IN-9 (Icarisids E) (Compound 2) is a potent xanthine oxidase (XOD) inhibitor with an IC50 of 31.81 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameXanthine oxidase-IN-9
-
NoteResearch use only, not for human use.
-
Brief DescriptionXanthine oxidase-IN-9 (Icarisids E) (Compound 2) is a potent xanthine oxidase (XOD) inhibitor with an IC50 of 31.81 μM.
-
DescriptionXanthine oxidase-IN-9 (Icarisids E) (Compound 2) is a potent xanthine oxidase (XOD) inhibitor with an IC50 of 31.81 μM.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
RecptorIC50: 31.81 μM (XOD)
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number2571069-61-7
-
Formula Weight826.79
-
Molecular FormulaC38H50O20
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ye ZJ, et al. New prenylflavonol glycosides with xanthine oxidase inhibitory activity from the leaves of Cyclocarya paliurus. Bioorg Chem. 2020 Aug;101:104018.?
molnova catalog
related products
-
Crenulatin
Crenulatin has dual- direction effects on apoptosis of cerebral microvascular endothelial cells, inhibitive effect in 25 mg/L and stimulative effect in 100 mg/L group, respectively; the mechanism is related to the alterations of Fas/Bcl-2 expression and caspase-3 activity.
-
ZK824190
ZK824190 is an orally available and selective inhibitor of urokinase plasminogen activator (uPA).
-
Avatrombopag
Avatrombopag is a new oral thrombopoietin (TPO) receptor agonist activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production.
